Business Wire

Celltrion Healthcare presents positive results for CT-P10, biosimilar rituximab, in advanced follicular lymphoma at the American Society of Hematology Meeting 2018

Del

Celltrion Healthcare today presented new data at the American Society of Hematology Meeting (ASH) 2018, which shows that the efficacy and safety of CT-P10 is comparable to reference rituximab in patients with advanced follicular lymphoma (AFL) over two years.1

The efficacy and safety of CT-P10 was evaluated in a randomized, double-blind, Phase III study which evaluated the overall survival (OS), progression-free survival (PFS), and sustained response in comparison to the reference biologic rituxan. The median follow-up duration was 23 months.i

140 patients were enrolled in a 1:1 ratio and 124 patients completed eight cycles of chemotherapy (R-CVP induction). 122 patients (62 patients in the CT-P10 group and 60 patients in the reference rituximab group) who showed response during the induction period, entered the maintenance period where a total of 12 cycles of rituximab monotherapy was to be administered every two months.i

The results showed that at the median follow-up duration of 23 months, the updated efficacy data in AFL patients demonstrated comparable OS (2-year OS of 93.2% and 95.3% for CT-P10 and reference rituximab, respectively) and PFS (2-year PFS was 75.2% and 73.5% for CT-P10 and reference rituximab, respectively). In terms of sustained response, the proportion of patients who showed relapse or disease progression after achieving overall response was 19.4% (13/67) in the CT-P10 group and 21.3% (13/61) in the reference rituximab group. CT-P10 was also well-tolerated and its safety profile including immunogenicity of CT-P10 was comparable to that of reference rituximab over 23 months of treatment.i

Christian Buske, Professor, Medical Director at the Comprehensive Cancer Center Ulm, Germany, Institute of Experimental Cancer Research and Attending Physician and Professor of Medicine at the Medical Department for Internal Medicine III, Hematology/Oncology, University Hospital Ulm said, “CT-P10 has already demonstrated non-inferiority of efficacy compared with reference rituximab combined with CVP in previously untreated AFL. The study results presented today have further strengthened these findings, showing no statistically meaningful difference between CT-P10 and reference rituximab for over two years and demonstrating a proven safety profile. I believe that these results will help to further increase physician confidence in using rituximab biosimilars and will broaden AFL patient access to efficacious and affordable therapies.”

Mr HoUng Kim, Head of Strategy and Operations Division, Celltrion Healthcare, said: “The two-year study marks another significant milestone for Celltrion Healthcare, showing that CT-P10 is comparable to reference rituximab in terms of overall survival and progression-free survival. Now that CT-P10 is approved in the US, the availability of the first rituximab biosimilar has the potential to significantly improve access to rituximab for patients with non-Hodgkin’s lymphoma indications. As a cost-effective alternative to the reference product, CT-P10 will reduce the burden on healthcare systems resulting in better patient outcomes.”

Also presented at ASH and published in The Lancet Haematology, is data from the CT-P10 3.4 LTBFL trial which aimed to demonstrate therapeutic equivalence of CT-P10 to reference rituximab (as monotherapy) in patients with previously untreated Low Tumor Burden Follicular Lymphoma (LTBFL).2

The results showed that CT-P10 was well-tolerated and the safety profile was comparable to that of reference rituximab over seven months. 108 (83%) of 130 patients assigned to CT-P10 and 104 (81%) of 128 assigned to rituximab achieved an overall response by month seven (treatment difference estimate 1·8%; 90% CI –6·43 to 10·20) and therapeutic equivalence was shown (90% CIs were within the prespecified margin of 17%).ii

CT-P10 is the first rituximab biosimilar to be approved in the United States.3

--- Ends---

Notes to editors:

About CT-P10 (biosimilar rituximab)
CT-P10 is a mAb that targets CD20, a transmembrane protein found on the surface of most B cells. By binding specifically to CD20, CT-P10 depletes B cells by three main mechanisms: Induction of apoptosis, stimulation of CDC (complement-dependent cytotoxicity) and stimulation of ADCC (antibody-dependent cell-mediated cytotoxicity). CT-P10 is approved in the EU for the treatment of patients with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. Further details of the approved indications and safety information for CT-P10 are available in the summary of product characteristics (SmPC).4 Celltrion and Teva Pharmaceutical Industries Ltd. entered into an exclusive partnership in October 2016 to commercialize CT-P10 (Truxima®) in the U.S. and Canada.

About Advanced FL
Follicular lymphomas are the second most frequent subtype of nodal lymphoid malignancies in Western Europe5 and are a subtype of NHL.6 It is a slow-growing lymphoma that develops from B lymphocytes (B cells). It is characterised by painless swelling of the lymph nodes, fever for no apparent reason, drenching night sweats, fatigue, infections and bleeding. Most cases are advanced at the time of diagnosis but since the advent of rituximab, overall survival has increased to in excess of 20 years. It is called ‘follicular’ lymphoma because the abnormal lymphocytes often collect in lymph nodes in clumps that are known as ‘follicles’. Follicular lymphoma is more common in people aged over 65, but it can occur in people of any age.

About Celltrion Healthcare
Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines. For more information please visit: http://www.celltrionhealthcare.com/

References

1 Kim, WS, et al. Similar Efficacy and Safety of CT-P10 and Reference Rituximab in Patients with Advanced Stage Follicular Lymphoma: Updated Phase III Study Results. 60th American Society of Hematology (ASH) Annual Meeting & Exposition 2018; 1616.

2 Ogura, M, et al. Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study. 60th American Society of Hematology (ASH) Annual Meeting & Exposition 2018; 1596.

3 FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma [news release]. FDA’s website. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm627009.htm [last accessed December 2018].

4 Truxima concentrate for solution for infusion summary of product characteristics [last accessed December 2017]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004112/WC500222694.pdf.

5 Dreyling, M, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v83-v90 doi:10.1093/annonc/mdw400.

6 Kohrt HEK & Ugarte A. Follicular Lymphoma: a Guide for Patients. European Society for Medical Oncology. 2014. Available at: https://www.esmo.org/content/download/52236/963497/file/EN-Follicular-Lymphoma-Guide-for-Patients.pdf [last accessed December 2018].

Contact information

Emma Gorton
egorton@hanovercomms.com
+44 203 817 6591

Georgia Featherston
gfeatherston@hanovercomms.com
+44 203 817 6718

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Planview Empowers Organizations to Realize Agile-at-Scale with Lean and Agile Delivery Solution18.2.2019 15:05:00Pressemelding

Today’s increasingly competitive and disrupted markets require teams and enterprises to adapt quickly and speed delivery of innovative products, solutions, and customer experiences. While agile ways of working have produced positive results on single teams, leveraging Agile across the organization creates a challenge – how to scale delivery across teams for larger initiatives and focus on business outcomes for driving change and results. The Planview® solution for Lean and Agile delivery solves this challenge by connecting agile delivery with strategic planning and lean portfolio management to achieve business objectives faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005030/en/ The Planview solution for Lean and Agile delivery connects strategic planning, lean portfolio management, and work delivery. (Graphic: Business Wire) “When Planview came together with LeanKit® in December 2017, we significantly expanded

The University of Luxembourg Launches a Unique Interdisciplinary Space Master in Line with the Government’s SpaceResources.lu Initiative18.2.2019 14:07:00Pressemelding

In fall 2019, the University of Luxembourg launches a two-year Interdisciplinary Space Master program. This Master study program, set up in collaboration with the Luxembourg Space Agency, aims to provide students with the engineering skills required in the burgeoning space industry, along with in depth knowledge to manage space-related business activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005215/en/ Etienne Schneider, Deputy Prime Minister and Minister of the Economy ; Stéphane Pallage, Rector of the University of Luxembourg ; Claude Meisch, Minister for Higher Education and Research © University of Luxembourg (Photo: Business Wire) In 1985, a public-private partnership effort launched Société Européenne des Satellites, today known as global satellite operator SES. Over the last decades, further space-related services and businesses have developed alongside SES shaping a vibrant space economy. As a leader

Wipro Launches QuMiC to Accelerate Migration to Oracle Cloud18.2.2019 13:55:00Pressemelding

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of QuMiC (Quick Migration to Cloud), a comprehensive platform designed to transform the way organizations migrate to Oracle Cloud. Using QuMiC, Wipro and Oracle aim to simplify and accelerate the journey to Oracle Cloud for their customers. Wipro is a Platinum level member of Oracle PartnerNetwork (OPN). Wipro’s QuMiC is a unique platform that migrates all aspects required for a cloud implementation, i.e. process definitions, configurations, data, and code to Oracle Cloud for a wide variety of software environments. Irrespective of whether an organization’s original assets are in an on-premise platform such as Oracle E-Business Suite, a version management tool, or another cloud software-as-a-service (SaaS) environment, QuMiC can automate and thereby, seamlessly accelerate the migration process. The platform reduces the

Top Mobility Firms Combine to Form Sterling Lexicon18.2.2019 13:47:00Pressemelding

Two of the mobility industry’s most trusted leaders – Lexicon Relocation and Sterling Mobility – this week announced the launch of their new brand, Sterling Lexicon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005205/en/ In mid-2018, Lexicon Relocation acquired Sterling Mobility, expanding their combined global footprint and service offerings in the mobility marketplace. After six months of integration, the companies have rolled out as one unified, global brand. The integration of the two companies enables Sterling Lexicon to deliver end-to-end services around the world. Focused on personalized, high-touch and quality solutions, Sterling Lexicon’s global employees expertly manage any relocation needs for private and corporate customers. “Individually, Lexicon and Sterling were highly regarded in the relocation industry, with a reputation for outstanding customer service. Together, we bring an unparalleled level of c

Milrem Robotics’ THeMIS UGV Strengthens Its Position as The Industry Standard18.2.2019 13:00:00Pressemelding

The unmanned warfare systems developer Milrem Robotics is the most represented company in its field at this year’s IDEX with the widest selection of different weaponized unmanned ground systems on display. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005105/en/ Together with industry partners MBDA, Electro Optic Systems, ST Engineering and Nexter, Milrem Robotics is exhibiting four different weaponized unmanned ground systems at the main defence event in the Middle East. All systems are integrated onto Milrem Robotics' THeMIS unmanned ground vehicle. (Photo: Business Wire) Together with industry partners MBDA, Electro Optic Systems, ST Engineering and Nexter, Milrem Robotics is exhibiting four different weaponized unmanned ground systems at the main defence event in the Middle East. All systems are integrated onto Milrem Robotics’ THeMIS unmanned ground vehicle. On display are two completely new weaponized UGVs – the

Saudi Arabia Ministry of Health and Masimo Announce Automation of National Neonatal CCHD Screening Process Using Masimo Technology18.2.2019 13:00:00Pressemelding

Recently at Arab Health 2019, the Saudi Arabia Ministry of Health (MOH) and Masimo (NASDAQ: MASI) jointly announced the implementation of an automation solution designed to streamline the process of critical congenital heart disease (CCHD) screening of newborns using Masimo SET®, the first automation of its kind worldwide. This latest phase in Saudi Arabia’s national CCHD screening program, which began in 2016 as part of the Vision 2030 plan addressing improvements in healthcare and other areas, automates the collection and storage of screening data, helping to make the process both more efficient and more accurate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005021/en/ Masimo Rad-97™ with Eve™ (Photo: Business Wire) In 2016, Saudi Arabia implemented a mandatory CCHD screening program for all newborns using the Masimo Eve™ Newborn Screening Application on Radical-7® Pulse CO-Oximeters® with SET® Measure-through Moti